C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke
Phase of Trial: Phase IV
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Brain extract (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms C-REGS2
- Sponsors EVER Neuro Pharma
- 06 Feb 2019 Planned End Date changed from 30 Sep 2020 to 30 Mar 2021.
- 06 Feb 2019 Planned primary completion date changed from 31 Mar 2020 to 30 Sep 2020.
- 07 May 2018 Planned End Date changed from 31 Mar 2020 to 30 Sep 2020.